Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Covalent Signs $2.3 Million Contract for Cardiovascular Drug Trial | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Covalent Signs $2.3 Million Contract for Cardiovascular Drug Trial

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Covalent Group, Inc. has signed a $2.3 million contract with a biotechnology company for the conduct of a multinational Phase II trial of a new anti-thrombotic agent. This trial will assess the efficacy and safety of the study drug in an at-risk patient population. Work on the study is expected to begin immediately. Covalent will provide multiple services including consulting on trial design and protocol development, project and study site management, field operations, data management, biostatistical support, and medical writing. Revenues will be recognized on a proportional performance basis over the life of the contract as services are performed.

Kenneth M. Borow, M.D., Covalent Group’s president and chief executive officer, commented, “We are delighted to have been chosen by this new client to work on this Phase II trial involving a novel cardiovascular agent. If this trial is successful, it is anticipated that additional clinical research trials will be conducted by the Sponsor and that Covalent will be well positioned to participate in this potentially large development program.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters